메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

'김갑성' 기자의 전체기사

Manulife Hong Kong and Macau Strengthens Leadership…

HONG KONG, Aug. 25, 2025 -- Manulife Hong Kong and Macau are pleased to announce three senior leadership appointments that underscore its commitment to executing strategic priorities and accelerating business growth. Danny Lee has been named Chief Health Officer, KC Cheung as Chief Product Officer, and Louisa Li as Chief Strategy Officer and Head of Macau Branch. These appointments reflect the company's sharpened focus on advancing its health proposition, driving product innovation, strengthening strategic planning, and accelerating expansion in the Macau market. Danny Lee Appointed Ch
- 김갑성 기자
- 2025-08-25 12:00
Harbour BioMed Appoints Yajie Li as Chief Medical Officer

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Aug. 25, 2025 -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology and oncology, today announced the appointment of Yajie Li as Chief Medical Officer (CMO). Ms. Li will be based in Shanghai and report directly to Dr. Jingsong Wang, Founder, Chairman and Chief Executive Officer of Harbour BioMed. In this role, Ms. Li will lead clinical development, regulatory strategy, and medical affair
- 김갑성 기자
- 2025-08-25 09:00
Innovent Biologics Announces U.S. FDA IND Approval for the Fir…

SAN FRANCISCO and SUZHOU, China, Aug. 25, 2025 -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company committed to developing, manufacturing and commercializing high-quality medicines in oncology, cardiovascular and metabolic diseases, autoimmune, ophthalmology and other major therapeutic areas, today announced that the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application to initiate a global Phase 3 clinical trial (MarsLight-11) of IBI363 in immunotherapy(IO)-resistant squamous non-small cell lun
- 김갑성 기자
- 2025-08-25 08:00
MALAYSIA HEALTHCARE TRAVEL COUNCIL LAUNCHES MH WELLNESS FAIR…

KUALA LUMPUR, Malaysia, Aug. 23, 2025 -- The Malaysia Healthcare Travel Council (MHTC) today launches the first edition of its MH Wellness Fair 2025 series, themed "Young & Healthy Champions", in conjunction with the United Nations' International Youth Day that is celebrated every 12th August. The fair celebrates and empowers young people to take charge of their health and wellbeing. Held at The Campus, Ampang, the fair brings together leading health experts, fitness innovators, cultural performers, and wellness brands under one roof. With the aim of empowering co
- 김갑성 기자
- 2025-08-23 17:46
엔젤얼라인 테크놀로지, "특허 침해 아냐, 적극 방어할 것"

샌클레멘테, 캘리포니아주, 2025년 8월 23일 -- 엔젤얼라인 테크놀로지(Angelalign Technology, 이하 "엔젤")가 얼라인 테크놀로지(Align Technology, ALGN)의 특허 침해 의혹을 전면 부인하며 적극적인 방어 의지를 피력했다. 엔젤의 리치 허쉬랜드(Rich Hirschland) 최고상업책임자(CCO) 겸 수석부사장은 "앤젤은 20년 넘게 임상을 중심으로 혁신을 일궈 온 역사가 있다. 경쟁사의 특허 위반 의혹 제기는 경솔하고 실익이 전혀 없는 것"이라며 "앤젤은 창립 이후 특허 관련 법규 준수에 막대한 투자를 했다. 이번 소송에서 승소를 확신한다"고 말했다. 앤젤은 오랫동안 클리어 얼라이너 분야에서 혁신을 선도했다. 첨단 제품으로는 수상 경력을 자랑하는 angelButton™과 angelHook, A6 하악 전진 시스템(올해 출시 10주년), angelKid 시스템, Intelligent Root System이 있다. 앤젤은 공정하고 건전한 경쟁을 통해 의사와 환자에게 기여하고자 최선을 다하고 있다
- 김갑성 기자
- 2025-08-22 23:04
WINVEST GROUP SUBSIDIARY IQI MEDIA PARTNERS WITH BIOCALTH TO DRIVE…

RENO, Nev., Aug. 22, 2025 -- Winvest Group Limited (OTCQB: WNLV) ("Winvest"), an investment holding company with diverse media, entertainment, and technology portfolios, is pleased to announced that its subsidiary IQI Media Inc. has partnered with BioCalth International Inc., a world leader in the development of proprietary health supplements, to help BioCalth grow its direct-to-consumer sales. The two companies have entered into a content management agreement with profit-sharing incentives that they hope will lead to a long-term relationship marked by increased reven
- 김갑성 기자
- 2025-08-22 20:00
Antengene Announces 2025 Interim Financial Results Highlig…

The Phase I/II CLINCH study of ATG-022 (CLDN18.2 antibody-drug conjugate) demonstrated promising results, showing robust clinical efficacy and a favorable safety profile in patients with gastric/gastroesophageal junction adenocarcinoma across high, low, and ultra-low CLDN18.2 expression levels. Supported by these results, ATG-022 was granted a Breakthrough Therapy designation by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA). The Phase I/II STAMINA study of ATG-037 (Oral CD73 small molecule inhibitor) is progressing smoothly. The la
- 김갑성 기자
- 2025-08-22 18:14
Angel Yeast Cup Finals and Industry Development Conferen…

Engaging the World Through Fermented Flour-Based Foods SHANGHAI, Aug. 22, 2025 -- The Finals of the 8th Angel Yeast Cup Chinese Fermented Dim Sum Contest and the 12th Fermented Flour-Based Food Industry Development Conference wrapped up in Ningxiang, Hunan province, a region widely recognized as the birthplace of Chinese staple foods. Sponsored and organized by Angel Yeast Co., Ltd. (SH600298), the event brought together 26 youth teams from different countries and regions alongside leading experts, researchers, industry representatives, and skilled food artisans specializing in
- 김갑성 기자
- 2025-08-22 18:04
MALAYSIA SHOWCASES HEALTHCARE EXCELLENCE IN CAMBODIA, DRIVING M…

KUALA LUMPUR, Malaysia, Aug. 22, 2025 -- The Malaysia Healthcare Travel Council (MHTC) proudly presents Malaysia Healthcare Week 2025 in Phnom Penh, Cambodia, an initiative designed to strengthening healthcare ties between the two nations and position Malaysia as the medical tourism destination in the world. Taking place from 19 to 22 August 2025, the event features a series of engagements including medical sharing sessions, business-to-business (B2B) meetings, public outreach programmes, and networking events with Cambodian stakeholders, healthcare facilitators, and the expatr
- 김갑성 기자
- 2025-08-22 11:00
Biosyngen Unveils Innovative Strategies for Next-Generation T…

SINGAPORE, Aug. 22, 2025 -- Asia Bio Innovation Summit 2025 is one of the premier industry-focused events in Asia and focus on the hottest topics of ADC and CGT. Asia Bio Innovation summit 2025 Singapore brought together 30+ world-class Speakers, 10+ Exhibitors and 200+ Attendees from regulatory authority, big pharma, biotech, academia, CXO and etc, to harness the full potential of ADC and Cell & Gene Therapy across 2 days of content. Dual Engines of Innovation: ADC and CGT Drive Global Collaboration The summit spotlighted antibody-drug conjugates (ADCs) and cell and
- 김갑성 기자
- 2025-08-22 09:55

이전

61 62 63 64 65 66 67 68 69 70

많이 본 기사

최근기사

2025-10-22_WED

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 10월 22일 19시 40분